Octagon Capital Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Octagon Capital Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,000	Closed	-$1.65M	–	45
2022 Q4	$1.65M	Buy	+15,000	New	+$973K	0.26%	28
2022 Q3	–	Sell	-80,000	Closed	-$2.26M	–	40
2022 Q2	$2.26M	Hold	80,000	–	–	0.6%	17
2022 Q1	$3.02M	Sell	80,000 -120,000	-60%	-$4.74M	0.65%	21
2021 Q4	$7.91M	Hold	200,000	–	–	1.54%	16
2021 Q3	$4.74M	Hold	200,000	–	–	1.17%	19
2021 Q2	$4.91M	Hold	200,000	–	–	1.02%	25
2021 Q1	$3.65M	Buy	+200,000	New	+$4.13M	1.38%	26

Other funds holding RXDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's RXDX Position: Q1 2023 in Review

Octagon Capital Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 15,000 shares — an estimated $1.65M sold.

Octagon Capital Advisors first reported a position in RXDX in Q1 2021 and held it in 7 quarters. The position peaked at $7.91M in Q4 2021. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

Octagon Capital Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Octagon Capital Advisors sold 15,000 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $1.65M.
Octagon Capital Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Octagon Capital Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $7.91M in Q4 2021.
219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on Octagon Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.